Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan;2(1):286-97.
doi: 10.1159/000339730. Epub 2012 Aug 8.

Video Rating in Neurodegenerative Disease Clinical Trials: The Experience of PRION-1

Affiliations

Video Rating in Neurodegenerative Disease Clinical Trials: The Experience of PRION-1

Christopher Carswell et al. Dement Geriatr Cogn Dis Extra. 2012 Jan.

Abstract

Background/aims: Large clinical trials including patients with uncommon diseases involve assessors in different geographical locations, resulting in considerable inter-rater variability in assessment scores. As video recordings of examinations, which can be individually rated, may eliminate such variability, we measured the agreement between a single video rater and multiple examining physicians in the context of PRION-1, a clinical trial of the antimalarial drug quinacrine in human prion diseases.

Methods: We analysed a 43-component neurocognitive assessment battery, on 101 patients with Creutzfeldt-Jakob disease, focusing on the correlation and agreement between examining physicians and a single video rater.

Results: In total, 335 videos of examinations of 101 patients who were video-recorded over the 4-year trial period were assessed. For neurocognitive examination, inter-observer concordance was generally excellent. Highly visual neurological examination domains (e.g. finger-nose-finger assessment of ataxia) had good inter-rater correlation, whereas those dependent on non-visual clues (e.g. power or reflexes) correlated poorly. Some non-visual neurological domains were surprisingly concordant, such as limb muscle tone.

Conclusion: Cognitive assessments and selected neurological domains can be practically and accurately recorded in a clinical trial using video rating. Video recording of examinations is a valuable addition to any trial provided appropriate selection of assessment instruments is used and rigorous training of assessors is undertaken.

Keywords: Clinical trial; Creutzfeldt-Jakob disease; PRION-1; Rating scale; Video rating.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Creutzfeldt-Jakob disease patients were assessed by the bedside and remotely by video recording. The inter-assessor variability between the assessments is shown using the kappa statistic for cognitive examination (a), overall impression (b), and neurological examination (c).
Fig. 2
Fig. 2
Bland Altman plots describing the variability of agreement throughout the range of each examination scale between bedside and remote assessments of Creutzfeldt-Jakob disease patients in the PRION-1 trial for the domains: a Calculation, b Letter Cancellation, and c Overall extrapyramidal assessment.

References

    1. Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009;73:2061–2070. - PMC - PubMed
    1. Kieburtz K, McDermott MP, Voss TS, et al. A randomized, placebo-controlled trial of latrepirdine in Huntington disease. Arch Neurol. 2010;67:154–160. - PMC - PubMed
    1. Green RC, Schneider LS, Amato DA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA. 2009;302:2557–2564. - PMC - PubMed
    1. Doody RS, Gavrilova SI, Sano M, et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008;372:207–215. - PubMed
    1. Feldman HH, Doody RS, Kivipelto M, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010;74:956–964. - PubMed